Quantifying ultra-rare pre-leukemic clones via targeted error-corrected sequencing

Leukemia

Volumn 29, Issue 7, 2015, Pages 1608-1611

  Young, A L ^a   Wong, T N ^a   Hughes, A E O ^a   Heath, S E ^a   Ley, T J ^a   Link, D C ^a   Druley, T E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA FORMAMIDOPYRIMIDINE GLYCOSYLASE; NUCLEOTIDE; OLIGONUCLEOTIDE; TRANSCRIPTION FACTOR RUNX1;

ACUTE MYELOBLASTIC LEUKEMIA; BIOINFORMATICS; CONSENSUS SEQUENCE; DILUTION; GENE SEQUENCE; GENE TARGETING; HEMATOPOIESIS; HUMAN; LETTER; LEUKEMIA; LIMIT OF DETECTION; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; NONSENSE MUTATION; PRIORITY JOURNAL; QUALITY CONTROL; SOMATIC MUTATION; CELL CLONE; DNA SEQUENCE; GENETICS; HIGH THROUGHPUT SEQUENCING; PATHOLOGY; POLYMERASE CHAIN REACTION; STANDARDS;

CLONE CELLS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA, MYELOID, ACUTE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 84937023785     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.17     Document Type: Letter

References (14)

1. Holstege H, Pfeiffer W, Sie D, Hulsman M, Nicholas TJ, Lee CC, et al. Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis. Genome Res. 2014; 24: 733-742
2. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012; 366: 1090-1098
3. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The Origin and Evolution of Mutations in Acute Myeloid Leukemia. Cell. 2012; 150: 264-278
4. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci USA. 2012; 109: 14508-14513
5. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA. 2011; 108: 9530-9535
6. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008; 35: 418-429
7. Wong T, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. The role of TP53 mutations in the origin and evolution of therapy-related AML. Nature. 2015; 518: 552-555
8. Fu GK, Xu W, Wilhelmy J, Mindrinos MN, Davis RW, Xiao W, et al. Molecular indexing enables quantitative targeted RNA sequencing and reveals poor efficiencies in standard library preparations. Proc Natl Acad Sci USA. 2014; 111: 1891-1896
9. Lou DI, Hussmann Ja, McBee RM, Acevedo A, Andino R, Press WH, et al. High-Throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing. Proc Natl Acad Sci USA. 2013; 110: 19872-19877
10. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368: 2059-2074
11. Salipante SJ, Fromm JR, Shendure J, Wood BL, Wu D. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing. Mod Pathol. 2014; 27: 1438-1446
12. Kohlmann a, Nadarajah N, Alpermann T, Grossmann V, Schindela S, Dicker F, et al. Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. Leukemia. 2014; 28: 129-137
13. Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, Wain J, et al. Performance comparison of benchtop high-Throughput sequencing platforms. Nat Biotechnol. 2012; 30: 434-439
14. Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol. 2013; 10: 460-471